Cholecalciferol and Ergocalciferol Replacement in Critically Injured Burn Patients: An Observational Cohort Study
Journal of Burn Care & Research · 2025
DOI: 10.1093/jbcr/irae149 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Burn Care & Research, 2025. Verfasst von Kees Vanderwyk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California Davis Health, Sacramento, CA 95817, USA. Hauptthemen laut MEDLINE: Burns, Ergocalciferols, Vitamin D Deficiency, Cholecalciferol. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Vitamin D deficiency appears to be more prevalent than previously considered in the adult critically ill population, specifically burn-injured patients. No definitive regimen has been shown to restore vitamin D (25(OH)D) levels more effectively to therapeutic levels in the burn-injured population. The purpose of this study was to investigate the effects of either ergocalciferol (D2, 50 000 IU weekly) or cholecalciferol (D3, 6000 IU daily) in adults with burns ≥10% TBSA. This retrospective, observational study (2020-2022) included patients with vitamin D insufficiency (<30 ng/mL) who received replacement and monitoring with weekly vitamin D levels. Patients on dialysis or those with a hospital length of stay less than 2 weeks were excluded. Forty-five patients treated with ergocalciferol and 99 patients with cholecalciferol were included in the study. Patients treated with cholecalciferol were more likely to achieve 25(OH)D levels greater than 30 ng/mL compared to ergocalciferol over a 42-day period (HR 23.56, [95% CI, 12.57-44.16], P < .0001). A higher proportion of patients in the cholecalciferol group achieved vitamin D greater than 20 ng/mL (HR 6.37, [95% CI, 4.20-9.66], P < .0001). The adjusted hazard ratios (D3 vs D2) for achieving 25(OH)D levels > 30 ng/mL and > 20 ng/mL were and 23.94 (95% CI 5.09-427.6, P = .0019) and 7.32 (95% CI, 3.83-15.52, P < .0001) respectively, after controlling for TBSA and initial 25(OH)D. Cholecalciferol appears to be a more effective agent than ergocalciferol for correcting vitamin D deficiency and insufficiency in patients with burn injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of California Davis Health, Sacramento, CA 95817, USA.
- School of Pharmacy, University of California San Francisco, San Francisco, CA 94143, USA.
- Food and Nutrition Services, University of California Davis Health, Sacramento, CA 95817, USA.
- Patient Care Services, University of California Davis Health, Sacramento, CA 95817, USA.
- Burn Surgery, University of California Davis Health, Sacramento, CA 95817, USA.
- Shriner's Hospital for Children Northern California, Sacramento, CA 95817, USA.
ORCID-Profile: Kees Vanderwyk, Sierra Young, Kristi Wong, Jessica La Force, Molly Alexander, Jeremiah J Duby
Zitieren
APA
Vanderwyk, K., Young, S., Louie, E., Wong, K., La Force, J., Alexander, M., Sen, S., & Duby, J. J. (2025). Cholecalciferol and Ergocalciferol Replacement in Critically Injured Burn Patients: An Observational Cohort Study. Journal of Burn Care & Research. https://doi.org/10.1093/jbcr/irae149
Vancouver
Vanderwyk K, Young S, Louie E, Wong K, La Force J, Alexander M, et al. Cholecalciferol and Ergocalciferol Replacement in Critically Injured Burn Patients: An Observational Cohort Study. Journal of Burn Care & Research. 2025. doi:10.1093/jbcr/irae149
BibTeX
@article{Vanderwyk2025,
author = {Vanderwyk, Kees and Young, Sierra and Louie, Erin and Wong, Kristi and La Force, Jessica and Alexander, Molly and Sen, Soman and Duby, Jeremiah J},
title = {Cholecalciferol and Ergocalciferol Replacement in Critically Injured Burn Patients: An Observational Cohort Study},
journal = {Journal of Burn Care & Research},
year = {2025},
doi = {10.1093/jbcr/irae149}
}
EUVIMED